Ipilimumab biosimilar (Henlius)

伊匹木单抗生物类似药 (复宏汉霖)

Report date: 2026/03/31 20:00:21

Base Information

Drug NameIpilimumab biosimilar (Henlius)
Drug Alias Name重组抗 CTLA-4 全人单克隆抗体注射液 (复宏汉霖)HLX13
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionAnti-CTLA4
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLiver Neoplasms +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSerbiaTurkey +[5] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Henlius Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrganon LLCShanghai Henlius Biotech IncShanghai Henlius Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungLiver NeoplasmsColorectal Neoplasms +[8] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A